Hungary's Richter, Palatin Technologies sign drug license deal

BUDAPEST, Sept 3 (Reuters) - Hungary's Richter and Palatin Technologies have signed a license agreement to co-develop and sell a drug called bremelanotide in the EU, other European countries and additional selected countries, the companies said on Wednesday.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.